SCHEMBL6397019

SCHEMBL6397019

CC(CC(O)c1cc(O)ccc1OP(=O)(O)O)c1ccc(O)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.36
ESR2 Q92731 2/20 0.36
INPPL1 O15357 6/20 0.35
INPP5A Q14642 3/20 0.35
AKT1 P31749 1/20 0.35
INPP5B P32019 1/20 0.34
LMNA P02545 2/20 0.33
ALDH1A1 P00352 2/20 0.32
HIF1A Q16665 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
SLC22A1 O15245 1/20 0.32
ADRB2 P07550 1/20 0.32
CHRM2 P08172 1/20 0.32
ADRB1 P08588 1/20 0.32
CYP3A4 P08684 1/20 0.32
CHRM1 P11229 1/20 0.32
TSHR P16473 1/20 0.32
NFKB1 P19838 1/20 0.32
SLC6A4 P31645 1/20 0.32
OPRM1 P35372 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6395991 0.90 ESR1 (0.36) ESR1ESR2INPPL1INPP5AAKT1
SCHEMBL6397897 0.89 HIF1A (0.38) INPPL1INPP5AAKT1INPP5BLMNA
SCHEMBL7613747 0.81 ESR1 (0.44) ESR1ESR2INPPL1INPP5AAKT1
SCHEMBL6397799 0.80 INPPL1 (0.38) ESR1ESR2INPPL1INPP5AAKT1
SCHEMBL6397329 0.80 ESR1 (0.38) ESR1ESR2LMNAALDH1A1HIF1A
SCHEMBL6398355 0.80 ESR1 (0.34) ESR1ESR2INPPL1INPP5AAKT1
SCHEMBL6397720 0.80 INPPL1 (0.40) ESR1ESR2INPPL1INPP5AAKT1
SCHEMBL6403599 0.79 HIF1A (0.38) INPPL1INPP5AINPP5BLMNAHIF1A
SCHEMBL7619925 0.79 INPPL1 (0.39) ESR1ESR2INPPL1INPP5AAKT1
SCHEMBL6397337 0.78 INPPL1 (0.38) ESR1ESR2INPPL1INPP5AINPP5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ESR1 2885/4885ESR2 2416/4885INPPL1 82/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 ESR1 3212/4885ESR2 2699/4885INPPL1 85/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ESR1 2885/4885ESR2 2416/4885INPPL1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.